239 lines
No EOL
18 KiB
HTML
239 lines
No EOL
18 KiB
HTML
<!-- Changed ON 09/24/2024 -->
|
||
<!-- Google Tag Manager -->
|
||
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
|
||
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
|
||
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
|
||
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
|
||
})(window,document,'script','dataLayer','GTM-T2DH393N');</script>
|
||
<!-- End Google Tag Manager -->
|
||
|
||
|
||
|
||
|
||
|
||
<HTML lang="en-US">
|
||
|
||
<!-- From NoticeTemplate.txt -->
|
||
|
||
|
||
|
||
|
||
<HEAD>
|
||
|
||
|
||
<TITLE>Expired NOT-AI-20-034: RESCINDED - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)</TITLE>
|
||
|
||
|
||
<META NAME="description" CONTENT="NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: RESCINDED - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) NOT-AI-20-034. NIAID">
|
||
<META NAME="Keywords" CONTENT="NOT-AI-20-034: RESCINDED - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<link href="../guide_styles/css/bootstrap.min.css" rel="stylesheet" media="screen">
|
||
<link href="../guide_styles/css/style.css" rel="stylesheet" media="screen">
|
||
<link href="../guide_styles/css/FOAM_Style.css" rel="stylesheet">
|
||
|
||
|
||
|
||
</HEAD>
|
||
|
||
<BODY>
|
||
|
||
|
||
<!--Start RESCINDED Block-->
|
||
<link type="text/css" rel="stylesheet" href="css/rescinded.css" media="all" />
|
||
<div class="noticeBar">This Notice was RESCINDED on July 6, 2020, please see <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-059.html">NOT-AI-20-059</a> that replaces it.</div>
|
||
<div id="watermark_background">
|
||
<p id="watermark_text">RESCINDED</p>
|
||
</div>
|
||
<!--End RESCINDED Block-->
|
||
|
||
|
||
|
||
|
||
|
||
<div class="container">
|
||
<div class="row">
|
||
<div class="col-xs-12">
|
||
|
||
|
||
|
||
|
||
<span class="title">RESCINDED - Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)</span>
|
||
|
||
<hr noshade>
|
||
|
||
<p><span class="heading3">Notice Number:</span>
|
||
<span class="title">NOT-AI-20-034</span></p>
|
||
|
||
<p><span class="heading3">Key Dates</span><br>
|
||
<strong>Release Date:</strong> March 25, 2020 (Rescinded July 6, 2020)<br>
|
||
<strong>First Available Due Date:</strong> March 25, 2020<br>
|
||
<strong>Expiration Date:</strong> March 25, 2021</p>
|
||
<span class="heading3">Related Announcements</span><br>
|
||
<a href="//grants.nih.gov/grants/guide/notice-files/NOT-AI-20-059.html">NOT-AI-20-059</a><br>
|
||
<a href="//grants.nih.gov/grants/guide/notice-files/NOT-AI-20-040.html">NOT-AI-20-040</a><br>
|
||
<a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html" target="_blank">PA-20-135</a>; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)
|
||
<p><span class="heading3">Issued by</span><br>
|
||
National Institute of Allergy and Infectious Diseases (<a href="https://www.niaid.nih.gov/" target="_blank">NIAID</a>)</p>
|
||
<p class="heading2">Purpose</p>
|
||
<div>
|
||
<p>NIAID is issuing this Notice of Special Interest (NOSI) to highlight the need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.</p>
|
||
<p>NIAID is therefore offering Competitive Revisions to active NIAID grants addressing research objectives described below.</p>
|
||
<p><strong>Background</strong></p>
|
||
<p>Coronaviruses are a diverse family of viruses that cause a range of disease in humans and animals, and there are currently no approved coronavirus vaccines or therapeutics. In January 2020, a novel coronavirus was identified as the causative agent of a now global pandemic of viral pneumonia. Current information regarding confirmed cases is changing daily and can be found on the Centers for Disease Control and Prevention website (<a href="https://www.cdc.gov/coronavirus/index.html" target="_blank">https://www.cdc.gov/coronavirus/index.html</a>) and through other sources. Transmission characteristics and the associated morbidity and mortality are not completely understood, but there is clear evidence of human-to-human transmission. Many other aspects of viral pathogenesis, natural history, and host range are poorly understood. Given this, there is an urgent public health need to better understand SARS-CoV-2/COVID-19, particularly to improve understanding of fundamental virology, immunology, and the development of animal models and medical countermeasures.</p>
|
||
<p><strong>Research Objectives</strong></p>
|
||
<p>In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications for Competitive Revisions to active grants to address the following research areas of interest:</p>
|
||
<ul>
|
||
<li>Studies to identify optimal <em>in vitro</em>culture requirements and conditions;</li>
|
||
<li>Development of reagents and assays for virus characterization;</li>
|
||
<li>Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;</li>
|
||
<li>Studies to identify viral epitopes critical for binding neutralization;</li>
|
||
<li>Studies to examine virus stability and persistence;</li>
|
||
<li>Production of molecular clones of SARS-CoV-2, reporter viruses and recombinant viral proteins;</li>
|
||
<li>Development of animal models of SARS-CoV-2 infection suitable for screening vaccine and therapeutic candidates and/or pathogenesis studies;</li>
|
||
<li>Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;</li>
|
||
<li>Virologic and serologic surveillance studies of the distribution and natural history of SARS-CoV-2 viruses in animal populations and in humans at the human/animal interface with particular emphasis on host reservoirs and understanding cross-species transmission events;</li>
|
||
<li>Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2;</li>
|
||
<li>Development of SARS-COV-2 therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of SARS-CoV-2 antiviral activity of existing or candidate therapeutics initially developed for other indications;</li>
|
||
<li>Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection and/or candidate vaccines, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and</li>
|
||
<li>Development of SARS-CoV-2 vaccine candidates that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.</li>
|
||
</ul>
|
||
</div>
|
||
<div>
|
||
<p><strong><strong>Application and Submission Information</strong></strong></p>
|
||
<p>Applications in response to this NOSI must be submitted using the following targeted funding opportunity:</p>
|
||
<ul>
|
||
<li><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html" target="_blank">PA-20-135</a>; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional), which is intended to provide funds for NIH grantees applying to <u>expand the scope </u>of their active grant.</li>
|
||
<li>The funding instrument, or activity code, will be the same as the parent award. All activity codes of currently funded NIAID grants are eligible.</li>
|
||
<li><em>Please note: NOT-AI-20-034 is specific for </em><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html" target="_blank"><em>PA-20-135</em></a><em>. NIH grantees seeking additional funds for research responsive to the SARS-CoV-2/COVID-19 outbreak that falls <u>within the scope</u> of an ongoing grant should instead apply for an administrative supplement under NIH PA-18-591, </em><a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html" target="_blank"><em>Administrative Supplements to Existing NIH Grants and Cooperative Agreements</em></a><em> FOA (</em><a href="https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html" target="_blank"><em>https://grants.nih.gov/grants/guide/pa-files/PA-18-591.html</em></a><em>).</em></li>
|
||
</ul>
|
||
<p><strong><strong>When developing applications in response to this NOSI, all instructions in the </strong><a href="https://grants.nih.gov/grants/how-to-apply-application-guide.html" target="_blank"><strong>SF424 (R&R) Application Guide</strong></a><strong> and </strong><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html" target="_blank">PA-20-135</a><strong> must be followed, with the following additions:</strong></strong></p>
|
||
<ul>
|
||
<li>The Research Strategy section of the application is limited to 6 pages.</li>
|
||
<li>The award project period of the Competitive Revision must not exceed two years.</li>
|
||
<li>Application budgets should not exceed the annual amount of the current parent award and should reflect the actual needs of the proposed project. Exceptions will be considered on a case-by-case basis.</li>
|
||
<li>Recipients may apply for work that is related to your funded project, whether within the scope or outside of the scope of the current project, regardless of the time remaining on the current project. Grants currently in an extension are eligible to apply.</li>
|
||
<li>Applications will be accepted on a rolling basis<strong> <strong>03/25/2020 from </strong><strong>03/25/2021 through </strong><strong>5:00 PM local time</strong> </strong>of the applicant organization. An application submitted in response to this NOSI that is received on <strong>03/25/2021</strong> or later, will be withdrawn.</li>
|
||
<li>Competitive revision applications to <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html" target="_blank">PA-20-135</a> must use the application form package with the Competition ID of NOT-AI-20-034-FORMS-E." This FOA will be reissued with a NOT-AI-20-034-FORMS-F package on May 25, 2020. Submissions to <a href="https://grants.nih.gov/grants/guide/pa-files/pa-18-935.html" target="_blank">PA-</a><a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html" target="_blank">20-135</a> must be completed by June 25, 2020 (see <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-026.html" target="_blank">NOT-OD-20-026</a> for details). Submissions to the reissued FOA will be accepted on or after May 25, 2020 through the expiration date of this Notice.</li>
|
||
<li><strong>IMPORTANT:</strong> For funding consideration, all applicants must designate <strong> NOT-AI-20-034 </strong> (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 (R&R) Form. <strong>Applications without this information in Box 4b will not be considered for this initiative.</strong></li>
|
||
<li>Investigators planning to submit an application in response to the NOSI are strongly encouraged to contact the program officers listed below to discuss the proposed project in the context of the parent award.</li>
|
||
<li>Review criteria, in addition to those described in <a href="https://grants.nih.gov/grants/guide/pa-files/PA-20-135.html" target="_blank">PA-20-135</a>: As applicable for the project proposed, reviewers will evaluate the following additional items and their responsiveness to the immediate need to help address a specific, public health crisis in a timely manner in accordance with the associated Emergency Guide Notice but will not give separate scores for these items.
|
||
<ul>
|
||
<li>Do the investigators have immediate access to the resources (e.g. patient samples, isolates, etc.) at sufficient quantities to achieve the aims of the proposed research?</li>
|
||
<li>If the proposed research will generate unique resources or data that may impact the public health response or medical countermeasure development, is the resource sharing plan adequate?</li>
|
||
</ul>
|
||
</li>
|
||
</ul>
|
||
</div>
|
||
<div></div>
|
||
<div>Applications nonresponsive to terms of this NOSI will be not be considered for the NOSI initiative.</div>
|
||
<p> </p>
|
||
<p class="heading2">Inquiries</p>
|
||
<div>Please direct all inquiries to the contacts in Section VII of the listed funding opportunity announcements with the following additions/substitutions:</div>
|
||
<div>
|
||
<p><strong>Scientific/Research Contact(s)</strong><br>
|
||
<br>
|
||
Diane Post, Ph.D.<br>
|
||
Respiratory Diseases Branch<br>
|
||
Division of Microbiology and Infectious Diseases (DMID)<br>
|
||
National Institute of Allergy and Infectious Diseases (NIAID)<br>
|
||
Telephone: 240-627-3348<br>
|
||
Email: <a href="/cdn-cgi/l/email-protection#bdcdd2cec9d9fdd3d4dcd4d993d3d4d593dad2cb"><span class="__cf_email__" data-cfemail="53233c202737133d3a323a377d3d3a3b7d343c25">[email protected]</span></a><br>
|
||
<br>
|
||
Halonna Kelly, Ph.D.<br>
|
||
Basic Immunology Branch<br>
|
||
Division of Allergy, Immunology, and Transplantation (DAIT)<br>
|
||
National Institute of Allergy and Infectious Diseases (NIAID)<br>
|
||
Telephone:240-627-3519<br>
|
||
Email: <a href="/cdn-cgi/l/email-protection#c7898e868e83e994869594f5e98988948e87a9aea6aea3e9a9aeafe9a0a8b1"><span class="__cf_email__" data-cfemail="26686f676f62087567747514086869756f66484f474f4208484f4e08414950">[email protected]</span></a><br>
|
||
<br>
|
||
<p>Martin Gutierrez<br>
|
||
Division of AIDS (DAIDS)<br>
|
||
National Institute of Allergy and Infectious Diseases (NIAID)<br>
|
||
Telephone: 240-292-4844<br>
|
||
Email: <a href="/cdn-cgi/l/email-protection#87eae0f2f3eee2f5f5e2fdc7e9eee6eee3a9e9eeefa9e0e8f1"><span class="__cf_email__" data-cfemail="c5a8a2b0b1aca0b7b7a0bf85abaca4aca1ebabacadeba2aab3">[email protected]</span></a></p>
|
||
<strong>Financial/Grants Management Contact(s)</strong><br>
|
||
<br>
|
||
Donna R. Sullivan<br>
|
||
Grants Management Program, DAIT Coordinator<br>
|
||
National Institute of Allergy and Infectious Diseases (NIAID)<br>
|
||
Telephone: 240-669-2979<br>
|
||
Email: <a href="/cdn-cgi/l/email-protection#84c0ebeaeae5aad7f1e8e8edf2e5eac4eaedecaae3ebf2"><span class="__cf_email__" data-cfemail="88cce7e6e6e9a6dbfde4e4e1fee9e6c8e6e1e0a6efe7fe">[email protected]</span></a><br>
|
||
<br>
|
||
Vandhana Khurana<br>
|
||
Grants Management Program, DMID Coordinator<br>
|
||
National Institute of Allergy and Infectious Diseases (NIAID)<br>
|
||
Telephone: 240-669-2966<br>
|
||
Email: <a href="/cdn-cgi/l/email-protection#42292a3730232c2334022c2b232b266c2c2b2a6c252d34"><span class="__cf_email__" data-cfemail="5b30332e293a353a2d1b35323a323f75353233753c342d">[email protected]</span></a></p>
|
||
<p>Ann Devine<br>
|
||
Grants Management Program, DAIDS Coordinator<br>
|
||
National Institute of Allergy and Infectious Diseases (NIAID)<br>
|
||
Telephone: 240-669-2988<br>
|
||
Email: <a href="/cdn-cgi/l/email-protection#65040100130c0b00250b0c040c014b0b0c0d4b020a13"><span class="__cf_email__" data-cfemail="5d3c39382b3433381d33343c343973333435733a322b">[email protected]</span></a></p>
|
||
</div>
|
||
<p> </p>
|
||
<p> </p>
|
||
|
||
|
||
|
||
|
||
|
||
</div>
|
||
</div>
|
||
|
||
|
||
<div class="row">
|
||
<div class="col-xs-12">
|
||
<P>
|
||
<HR>
|
||
<A HREF="/grants/guide/WeeklyIndex.cfm?03-27-20">Weekly TOC for this Announcement</A><br>
|
||
<A HREF="/grants/guide/index.html">NIH Funding Opportunities and Notices</A>
|
||
<hr>
|
||
</div>
|
||
</div>
|
||
<link rel="stylesheet" type="text/css" media="print" href="css/notices_print.css " />
|
||
|
||
|
||
|
||
|
||
|
||
<div class="row">
|
||
<div class="footer">
|
||
|
||
<div class="col-sm-4"> <a href="/grants/oer.htm"><img src="/images7/nih-oer-logo.jpg" alt="NIH Office of Extramural Research Logo" usemap="#Map2" border="0"></a>
|
||
<map name="Map2" id="Map2">
|
||
<area shape="rect" coords="89,17,359,39" href="http://www.nih.gov" />
|
||
<area shape="rect" coords="91,39,286,58" href="http://grants.nih.gov/grants/oer.htm" />
|
||
<area shape="rect" coords="3,5,78,55" href="http://grants.nih.gov/grants/oer.htm" />
|
||
</map>
|
||
</div>
|
||
<div class="col-sm-4">
|
||
<div style="float:left; padding: 5 5 5 70"> <a href="https://www.hhs.gov/"><img src="/images7/dhhs_sm.gif" width="36" height="37" border="0" alt="Department of Health and Human Services (HHS) - Home Page" long desc="Logo, circular in shape, depicting an American eagle in-flight with stylized profiles of human faces appearing on the trailing edge of the wings. The perimeter of the logo is encircled with the words 'Department of Health and Human Services U S A'"></a></div>
|
||
<div style="padding: 5 5 5 5;">Department of Health<br>
|
||
and Human Services (HHS)</div>
|
||
</div>
|
||
<div class="col-sm-4">
|
||
<div style="padding: 5 5 5 0" align="center"> <a href="https://www.usa.gov/"><img src="/images7/USA_Gov_logo.gif" border="0" alt="USA.gov - Government Made Easy" long desc="Logo,- the words 'USA.gov - Government Made Easy' with single streaking star above the logo"></a> </div>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
<div class="row">
|
||
<div class="footer">
|
||
<div class="col-xs-12" align="center" style="padding: 20 5 5 5"> <span style="color:#6E6E6E; font-size:1.0em; font-family: 'Trebuchet MS', Arial, Helvetica, sans-serif">NIH... Turning Discovery Into Health<sup>®</sup></span> </div>
|
||
</div>
|
||
</div>
|
||
|
||
|
||
<div class="row">
|
||
<div class="footer">
|
||
<div class="col-xs-12" align="center">
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</div>
|
||
|
||
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></BODY>
|
||
</HTML> |